| Business Review Weekly 2001 Beth QUinlivan |
| Title | Subject | Authors |
|---|
| Australia's drug lords.(pharmaceuticals)(Industry Overview) | Business, general | Beth Quinlivan |
| Big price, little value.(biotechnology company Marshall Edwards Inc) | Business, general | Beth Quinlivan |
| Big science, little money.(Australian commercialism in science) | Business, general | Beth Quinlivan |
| Biota catches a chill.(Australian developers of anti-influenza drug Relenza) | Business, general | Beth Quinlivan |
| Cashflow benefits from the plasma flow.(biotechnology company CSL) | Business, general | Beth Quinlivan |
| Circadian shares lose their rhythm. | Business, general | Beth Quinlivan |
| Cuckoos in the super nest.(superannuation savings) | Business, general | Maureen Murrill, Beth Quinlivan |
| Entigen's data hunter discovers US success.(profile of biological information provider Entigen)(Company Profile) | Business, general | Beth Quinlivan |
| Even experts forget the rules.(investments) | Business, general | Beth Quinlivan |
| Expansion is the Mayne game.(healthcare company Mayne Nickless) | Business, general | Beth Quinlivan |
| Faulding on the block.(F.H. Faulding, pharmaceuticals) | Business, general | Beth Quinlivan |
| Fear holds sway with risk.(Australian financial markets) | Business, general | Beth Quinlivan |
| Go carefully into investment clubs.(advice on investment clubs) | Business, general | Beth Quinlivan |
| 'Good' bugs on the grow. | Business, general | Beth Quinlivan |
| Health-care guru tries some first aid.(Sonic Healthcare, businessman Michael Boyd) | Business, general | Beth Quinlivan |
| Health funds are in recovery. | Business, general | Beth Quinlivan |
| Health's changing landscape.(includes related articles)(Australian health policies) | Business, general | Beth Quinlivan |
| Hype and high hopes.(biotechnology) | Business, general | Beth Quinlivan |
| Lights, camera, money.(Australian film industry) | Business, general | Beth Quinlivan |
| Market tests biotech's health. | Business, general | Beth Quinlivan |
| Medibank leads the charge.(privatisation) | Business, general | Beth Quinlivan |
| Melbourne a biotech magnet.(Melbourne, Australia) | Business, general | Beth Quinlivan |
| More change, more choice. | Business, general | Beth Quinlivan |
| New blood, new life. | Business, general | Beth Quinlivan |
| Singapore goes on a biotech spree. | Business, general | Beth Quinlivan |
| Small science is struggling.(includes related article)(Australian biotechnology industry) | Business, general | Beth Quinlivan |
| The first wave.(electronic commerce) | Business, general | Beth Quinlivan |
| The next code crackers.(biotech firms sought for research)(Brief Article) | Business, general | Beth Quinlivan |
| The price on pain.(includes related article)(pharmaceuticals, health service) | Business, general | Beth Quinlivan |
| The uncanny x-ray men.(Medical Imaging Australasia; includes related notes) | Business, general | Beth Quinlivan |
| Tiny cells, big money.(embryonic cell research) | Business, general | Beth Quinlivan |
| Who gets custody of the super?(superannuation) | Business, general | Beth Quinlivan |
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
